Shoko Nakajima
Yokohama City University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shoko Nakajima.
Pediatrics International | 2000
Shumpei Yokota; Tomoyuki Imagawa; Takako Miyamae; Shuichi Ito; Shoko Nakajima; Atsuo Nezu; Masaaki Mori
Abstract Background : To establish a treatment strategy for acute encephalopathy and encephalitis associated with influenza virus infection, the pathophysiology of the disease was investigated through manifestations and laboratory findings of patients.
Cytokine | 2009
Shoko Nakajima; Takuya Naruto; Takako Miyamae; Tomoyuki Imagawa; Masaaki Mori; Shigeru Nishimaki; Shumpei Yokota
Interleukin (IL)-6 is a causative agent of systemic juvenile idiopathic arthritis (sJIA), a chronic inflammatory disease complicated with severe growth impairment. Recent trials of anti-IL-6 receptor monoclonal antibody, tocilizumab, indicated that tocilizumab blocks IL-6/IL-6 receptor-mediated inflammation, and induces catch-up growth in children with sJIA. This study evaluates the effects of IL-6 on chondrogenesis by ATDC5 cells, a clonal murine chondrogenic cell line that provides an excellent model for studying endochondral ossification at growth plate. ATDC5 cells were examined for the expression of IL-6 receptor and gp130 by fluorescence-activated cell sorting analysis. Recombinant murine IL-6 was added to ATDC5 cultures to observe cell differentiation, using a quantitative RT-PCR for the chondrogenic differentiation markers type II collagen, aggrecan, and type X collagen. To block IL-6, the anti-mouse IL-6 receptor monoclonal antibody MR16-1 was added. As a result, the cells expressed IL-6 receptor and gp130. The expression of chondrogenic differentiation marker gene was reduced by IL-6, but this was abrogated by MR16-1. We conclude that IL-6 inhibits early chondrogenesis of ATDC5 cells suggesting that IL-6 may affect committed stem cells at a cellular level during chondrogenic differentiation of growth plate chondrocytes, and that IL-6 may be a cellular-level factor in growth impairment in sJIA.
Pediatrics International | 2009
Shigeru Nishimaki; Rumiko Higuchi; Shoko Nakajima; Takako Miyamae; Hiroaki Goto; Masaaki Mori; Shumpei Yokota
Background: The aim of the present study was to investigate the current conditions of psychological support for the families of children who died suddenly of disease or accident.
Modern Rheumatology | 2009
Shoko Nakajima; Takuya Naruto; Takako Miyamae; Tomoyuki Imagawa; Masaaki Mori; Shigeru Nishimaki; Shumpei Yokota
Modern Rheumatology | 2009
Akitaka Takahashi; Masaaki Mori; Takuya Naruto; Shoko Nakajima; Takako Miyamae; Tomoyuki Imagawa; Shumpei Yokota
Modern Rheumatology | 2013
Takayuki Kishi; Takako Miyamae; Ryoki Hara; Shoko Nakajima; Tomoyuki Imagawa; Masaaki Mori; Shumpei Yokota
The Journal of Rheumatology | 2004
Noriaki Tomono; Masaaki Mori; Shoko Nakajima; Takako Miyamae; Shuichi Ito; Toshihiro Mitsuda; Shumpei Yokota
Japanese journal of clinical immunology | 2005
Shoko Nakajima; Hiroaki Umebayashi; Rumiko Kurosawa; Tomoyuki Imagawa; Shigeki Katakura; Masaaki Mori; Yuko Aihara; Shumpei Yokota; Tuyoshi Sogo; Ayano Inui; Tomoo Fujisawa; Norio Hanzawa
Japanese journal of clinical immunology | 2008
Takako Miyamae; Shuichi Ito; Hiroyuki Machida; Remi Ozawa; Rumiko Higuchi; Shoko Nakajima; Tomoyuki Imagawa; Tomoko Nakamura; Masaaki Mori; Yuko Aihara; Kenji Ohshige; Shumpei Yokota
Ryūmachi. [Rheumatism] | 2003
Rumiko Kurosawa; Remi Umezawa; Yoshinori Kobayashi; Shoko Nakajima; Takako Miyamae; Shuichi Ito; Tomoyuki Imagawa; Shigeki Katakura; Masaaki Mori; Yukoh Aihara; Shumpei Yokota